G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase III Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

0
330
G1 Therapeutics, Inc. announced that the last patient has been randomized in the Phase III clinical trial of trilaciclib for patients with metastatic colorectal cancer receiving chemotherapy.
[G1 Therapeutics, Inc.]
Press Release